Nearing Finish Line, HCV Race Focuses On Salvage Therapy
With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.
You may also be interested in...
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.
Gilead Completes HCV Clinical Development With Vosevi Approval
Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.
AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients
Data from EXPEDITION-1 show a 99% SVR rate for HCV patients with compensated cirrhosis after 12 weeks of therapy. AbbVie also will present data at EASL on the utility of glecaprevir/pibrentasvir in CKD, post-liver or kidney transplant, HIV co-infected and treatment-failure patients.